Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723623 | 0.81 | ALDH1A1 (0.60) | ALDH1A1GFERMAPTKDM4ELMNA | |
| SCHEMBL10964657 | 0.78 | ERN1 (0.43) | ALDH1A1MAPTKDM4ETDP1MEN1 | |
| SCHEMBL4891804 | 0.75 | AKR1C3 (0.63) | ALDH1A1KDM4EPTPN1AKR1C4AKR1C3 | |
| SCHEMBL29593387 | 0.75 | AKR1C3 (0.63) | ALDH1A1KDM4EPTPN1AKR1C4AKR1C3 | |
| SCHEMBL9169776 | 0.75 | CA1 (0.45) | ALDH1A1GFERMAPTKDM4ELMNA | |
| SCHEMBL3238108 | 0.74 | GSK3B (0.41) | ALDH1A1MAPTKDM4ELMNAGAA | |
| SCHEMBL3243859 | 0.74 | ALDH1A1 (0.63) | ALDH1A1GFERMAPTKDM4ELMNA | |
| SCHEMBL28056380 | 0.73 | HSP90AB1 (0.43) | MAPTKDM4EPOLBMEN1KMT2A | |
| SCHEMBL23067380 | 0.72 | SNCA (0.56) | ALDH1A1GFERMAPTKDM4ELMNA | |
| SCHEMBL7244895 | 0.71 | PLAU (0.73) | ALDH1A1MAPTLMNAHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| US-10159678-B2 | Methods to decrease susceptibility to asthmatic bronchoconstriction | CORNELL UNIVERSITY (US) | 2018-12-25 | — | — | US | disclosed |
| EP-3045912-B1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING BV (NL) | 2018-09-19 | — | — | EP | disclosed |
| US-10006904-B2 | Rapid quantitative assay to measure CFTR function in a primary intestinal culture model | UMC UTRECHT HOLDING B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| EP-3045912-A1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC Utrecht Holding B.V. (NL) | 2016-07-20 | — | — | EP | disclosed |
| EP-2795322-B1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING BV (NL) | 2015-12-09 | — | — | EP | disclosed |
| US-20150276719-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-10-01 | — | — | US | disclosed |
| US-20150139915-A1 | METHODS TO DECREASE SUSCEPTIBILITY TO ASTHMATIC BRONCHOCONSTRICTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | disclosed |
| US-20150011420-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-01-08 | — | — | US | disclosed |
| WO-2013173595-A1 | METHODS TO DECREASE SUSCEPTIBILITY TO ASTHMATIC BRONCHOCONSTRICTION | WORGALL STEFAN (US) | 2013-11-21 | — | — | WO | disclosed |
| WO-2009105234-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH DEFECTS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE OR PROTEIN | COMBINATORX, INCORPORATED (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150139915-A1 | METHODS TO DECREASE SUSCEPTIBILITY TO ASTHMATIC BRONCHOCONSTRICTION | SMPD3, SMPD2, SMPD1 | ALDH1A1 1906/4885GFER 1855/4885MAPT 4759/4885 |
| US-10159678-B2 | Methods to decrease susceptibility to asthmatic bronchoconstriction | SMPD3, SMPD2, SMPD1 | ALDH1A1 1906/4885GFER 1855/4885MAPT 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.